R-ICE

Phase 1b/2 trial data showed that epcoritamab combined with R-ICE achieved an 87% overall response rate and a 65% complete response rate in relapsed/refractory DLBCL patients, with 65% proceeding to ASCT. These results, presented at EHA, suggest epcoritamab may improve ASCT eligibility and represent a potential new treatment option.